CD20在侵袭性癌症中的残留表达可能具有转化意义,这值得进一步的实验研究。 CD20 is the first-line diagnostic marker of B-cells, which serves as the target of the therapeutic monoclonal antibodies in B-cell lymphomas and leukemias. Recently, aberrant...
CD20在B淋巴细胞表面以寡聚体形式存在，现有实验证明CD20在B细胞表面形成的是四聚体。CD20与B细胞抗原受体（B cell antigen receptor，BCR）的膜型IgM（sIgM）存在相互作用已被被证实，B细胞活化后，BCR-CD20复合物会解离，磷蛋白、钙调素结合蛋白会暂时被招募到CD20，从而参与胞内信号的传导 [2-4]。2.2 CD20...
CD20 / MS4A1(B细胞标记)抗体,克隆L26(浓缩液),CD20 / MS4A1 (B-Cell Marker); Clone L26 (Concentrate) 其他 ScyTek公司始建于1991年,以成为世界级生命科学研究试剂生产商为目标。ScyTek从创立之初就采取了严格的原材料筛选程序,生产多种优质试剂,不断应用于各种学科,包括免疫学,组织学,细胞学,微生物学和...
套细胞淋巴瘤(mantle cell lymphoma,MCL)是一种罕见的 B 细胞非霍奇金淋巴瘤(nonhodgkin lymphoma,NHL)亚型,占 NHL 发病的 6% ~ 8%,其特征为反复缓解后复发,耐药情况普遍存在[1]。 恶性B 细胞淋巴瘤的发病机制通常与 B ...
finding, anti-CD20 treatment of human neuroimmunological disorders increased the relative frequency of monocytes and accentuated pro-inflammatory monocyte function; when reactivated ex vivo, a higher frequency of monocytes from B-cell depleted patients produced TNF and expressed the activation marker SLAM....
上海玉博生物科技有限公司 主要致力于“MOUSE ANTI-B CELL (CD20) (CLON Invitrogen-180088”的生产销售。多年的“MOUSE ANTI-B CELL (CD20) (CLON Invitrogen-180088”生产与销售的经验,与各行业新老用户建立了稳定的合作关系,我公司经营的产品名称深受广大用户信赖。欢
CD20+ B Cell Depletion Alters T Cell Homing Depleting mAbs against the pan B cell marker CD20 Laman,D J.,Tak,... - 《Journal of Immunology Official Journal of the American Association of Immunologists》 被引量: 14发表: 2014年 Characterization of angioimmunoblastic T-cell lymphomas (AILT) ...
CM Howard,S Anderson,B Harrington - 《Journal of Veterinary Diagnostic Investigation》 被引量: 0发表: 2024年 Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry These exosomes also expressed the B cell marker CD20, and the complement inhibitory...
CD20在B淋巴细胞表面以寡聚体形式存在,现有实验证明CD20在B细胞表面形成的是四聚体。CD20与B细胞抗原受体(B cell antigen receptor,BCR)的膜型IgM(sIgM)存在相互作用已被被证实,B细胞活化后,BCR-CD20复合物会解离,磷蛋白、钙调素结合蛋白会暂时被招募到CD20,从而参与胞内信号的传导 [2-4]。
Rituximab,a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20. Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis,complement activation and antibody dependent cellular cytotoxicity. Rituximab is...